Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · Real-Time Price · USD
9.53
+0.05 (0.53%)
At close: May 9, 2025, 4:00 PM
9.53
0.00 (0.00%)
After-hours: May 9, 2025, 4:00 PM EDT

Gyre Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22
Net Income
-12.09-92.932.3
Depreciation & Amortization
-1.591.111.13
Loss (Gain) From Sale of Assets
-0.073.340
Asset Writedown & Restructuring Costs
--83.1-
Loss (Gain) on Equity Investments
-0.041.310.25
Stock-Based Compensation
-0.837.2813.37
Provision & Write-off of Bad Debts
-0.17-0.060.02
Other Operating Activities
-4.446.021.4
Change in Accounts Receivable
--5.260.29-7.92
Change in Inventory
--2.141.75-0.88
Change in Accounts Payable
--0.250.19-0.11
Change in Income Taxes
--2.173-1.34
Change in Other Net Operating Assets
--13.0511.492.46
Operating Cash Flow
--3.6425.8910.68
Operating Cash Flow Growth
--142.50%-
Capital Expenditures
--2.32-8.52-4.99
Sale of Property, Plant & Equipment
-0.40.66-
Cash Acquisitions
--5.46-
Divestitures
---0.57-
Sale (Purchase) of Intangibles
--0.81-0.07-0.01
Investment in Securities
--17.16-16.74-8.82
Investing Cash Flow
--19.88-19.76-13.81
Issuance of Common Stock
-2.64--
Other Financing Activities
--0.54--
Financing Cash Flow
-2.12.5-
Foreign Exchange Rate Adjustments
--0.27-0.3-1.89
Net Cash Flow
--21.78.33-5.03
Free Cash Flow
--5.9617.385.69
Free Cash Flow Growth
--205.25%-
Free Cash Flow Margin
--5.63%15.32%5.56%
Free Cash Flow Per Share
--0.060.260.07
Cash Income Tax Paid
-8.526.356.31
Levered Free Cash Flow
--620.67-
Unlevered Free Cash Flow
--620.67-
Change in Net Working Capital
14.3915.44-8.85-
Updated May 9, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q